Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)

Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)

Abstract Background Novel and effective immunotherapies are required for refractory or recurrent sarcomas. Transforming growth factor-beta (TGF-β) is a diverse regulatory and fibrogenic protein expressed in multiple sarcoma tumors that promotes epithelial-mesenchymal transition and excessive deposit...

Full description

Bibliographic Details
Main Authors: Lu Xie, Xin Liang, Jie Xu, Xin Sun, Kuisheng Liu, Kunkun Sun, Yuan Li, Xiaodong Tang, Xianan Li, Xing Zhan, Xiaohui Niu, Wei Guo
Format: Article
Language:English
Published: BMC 2023-09-01
Series:BMC Cancer
Subjects:
PD-L1/TGF-β
Alveolar Soft Part Sarcoma (ASPS)
Osteosarcoma
Tumor immune microenvironment
Online Access:https://doi.org/10.1186/s12885-023-11390-4

Internet

https://doi.org/10.1186/s12885-023-11390-4

Similar Items